Nuvation Bio Inc. beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging -6.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.15 | $-0.15 | +0.0% | Beat | |
| Q1 FY26 | not reported | $0.01 | not reported | not reported | |
| Q4 FY25 | $-0.11 | $-0.11 | +0.0% | Beat | |
| Q3 FY25 | $-0.17 | $-0.16 | +5.9% | Beat | |
| Q2 FY25 | $-0.17 | $-0.17 | +0.0% | Beat | |
| Q1 FY25 | $-0.16 | $-0.16 | +0.0% | Beat | |
| Q4 FY24 | $-0.14 | $-0.15 | -7.1% | Miss | |
| Q3 FY24 | $-0.13 | $-0.15 | -15.4% | Miss | |
| Q2 FY24 | $-0.06 | $-0.15 | -150.0% | Miss | |
| Q1 FY24 | $-0.08 | $-0.07 | +12.5% | Beat | |
| Q4 FY23 | $-0.10 | $-0.06 | +40.0% | Beat | |
| Q3 FY23 | $-0.10 | $-0.09 | +10.0% | Beat |
Back to NUVB overview · NUVB holders · NUVB KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.